Creavo Medical Technologies

The firm focused on developing diagnostic technologies for acute medical settings, particularly for cardiology in emergency departments. Its main product was the Vitalscan, a portable device that uses magnetocardiography (MCG) to measure the magnetic fields produced by the heart's electrical activity. This non-invasive scan was designed to take three to five minutes at a patient's bedside, allowing physicians to quickly and accurately rule out ischaemic heart disease in patients presenting with chest pain. By identifying patients without cardiac-related issues, the technology aimed to reduce the need for lengthy and resource-intensive triage processes, such as multiple ECGs and blood tests, thereby saving hospitals time and money. The company's business model was centered on selling this device to healthcare providers, targeting a global market estimated to be in excess of £2 billion.

Creavo achieved several important milestones, including obtaining CE mark registration for Vitalscan in Europe and securing clearance from the U.S. FDA, validating the device for clinical use. The company also completed a major funding round to support large-scale clinical trials across the UK and the U.S., as well as to prepare for commercial rollout. However, according to UK government records, the company subsequently entered liquidation.